Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — warrants further investigation, according to researchers.

On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

The phase 4 PADMA study showed meaningful improvements in TFF and PFS in patients with high-risk HR-positive/HER2-negative metastatic breast cancer.

The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...

The objective response rate was 78.6% in the overall cohort, 76.9% in patients with a PD-L1 combined positive score (CPS) below 1, 68.8% in patients with a PD-L1 CPS of 1-9, and 100% in patients with ...

A new study explores PET-guided risk stratification to tailor salvage therapy in pediatric relapsed/refractory Hodgkin ...